Lung Cancer Clinical Trials

**OPENING SOON**

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

UC 06-15
SUSPENDED
Optical Coherence Tomography of Airway and Pleural Disorders (Brenner)

UC 16-01
Pathway Analyses for Individualized Network Therapeutics for Cancer (Ou)

UCI 14-25
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 14-36
A Correlative Study to Examine Cancer Molecular Alterations Using a Blood Based Assay (Seery)

UCI 15-79
Phase II Open-Label Randomized Radiosurgery w/ or w/o TT Fields for 1-10 Brain Metastases from NSCLC (Carrillo)

BLOOD DRAW ONLY

DIAGNOSTIC

FAILED PLATINUM-BASED CHEMO TX

NEW DX OF BRAIN METS

1st LINE THERAPEUTIC
楼盘已开放

**OPENING SOON**

UCI 07-40
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

UCI 16-96
A Phase 1 Study with Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors (Ou)

UCI 15-47
Ph. 3 Mpd13280a (Anti–Pd-L1 Antibody) Compared w/ BSC Following Adjuvant Cisplatin-Based Chem NSCLC (Ou)

UCI 12-44
A Phase II, open-label study of ponatinib, a multi-targeted oral tyrosine kinase inhibitor, in advanced NSCLC harboring RET translocations (Ou)

**UCI 17-50**
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumor (Ou)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**OPENING SOON**

0817
Lung Cancer Clinical Trials

Multiple Mutations

**UCI 14-39 SUSPENDED**
Phase I, Two-part, Multi-Center, Non-Randomized, Open Label, Multiple Dose First in Human Study of DS-6051B, an Oral ROS1 and NTRK Inhibitor, in Subjects with Advanced Solid

**UCI 13-49**
Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies (Ou)

**ECOG-EAY131**
Molecular Analysis for Therapy Choice (MATCH) (Seery)

**UCI 15-74**
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Seery)

**UCI 14-23**
Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations (Ou)

**UCI 15-71**
A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with Erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, locally advanced/metastatic NSCLC with acquired resistance to prior EGFR TKI (Ou)

**UCI 15-82**
A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease (Ou)

**UCI 16-79**
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Ou)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**OPENING SOON**